BPC-157 + TB-500 is a lyophilized research vial that contains two unrelated peptides in equal amounts by mass: BPC-157 and TB-500. The 10 mg vial holds 5 mg of each, at ≥98% purity. Both have been stu...
Certificate of Analysis included with every order.
Technical Specifications
Purity
≥98%
Form
Lyophilized powder
Storage
-20°C
Molecular Weight
Blend: BPC-157 1419.5 g/mol · TB-500 identity and MW per COA
Sequence
BPC-157 (GEPPPGKPADDAGLV) + TB-500, 1:1 by mass (10 mg vial = 5 mg + 5 mg)
CAS Number
BPC-157 137525-51-0 · TB-500 per COA
About BPC-157 + TB-500
BPC-157 + TB-500 is a lyophilized research vial that contains two unrelated peptides in equal amounts by mass: BPC-157 and TB-500. The 10 mg vial holds 5 mg of each, at ≥98% purity. Both have been studied mainly in animal models of tendon and wound healing.[1][6]
The two components
BPC-157: a stable 15-amino-acid peptide, GEPPPGKPADDAGLV, based on a gastric juice protein; molecular weight 1419.5 g/mol, CAS 137525-51-0.[1][10]
TB-500: a synthetic peptide based on thymosin beta-4 (Tβ4). The name is used for two molecules: doping-control analyses describe TB-500 as the N-acetylated 7-residue fragment LKKTETQ (889.0 g/mol), the actin-binding region of Tβ4, while the full-length 43-residue protein weighs about 4963 g/mol.[4][11][12] Products sold as TB500 have not always matched their description.[5] The identity of the TB-500 in each Pepitiva batch is documented in its Certificate of Analysis.
Evidence for the combination
One published study has tested this pair together: in a 2026 rat Achilles tendon model, the combination did not add benefit over either peptide alone.[8] Neither peptide is approved for human use.[5][9]
For research use only. Not for human consumption.
Quality & Storage
≥98% purity. Lyophilized powder. Storage: -20°C. For research purposes only.
Mechanism of Action
The two peptides act through different pathways, which is the rationale for testing them side by side:
BPC-157
Tendon fibroblasts: faster outgrowth from tendon explants, better cell survival under oxidative stress and dose-dependent migration through FAK-paxillin signaling.[2]
Angiogenesis: increased VEGFR2 expression and activation of VEGFR2-Akt-eNOS signaling in endothelial cells.[3]
TB-500 / thymosin β4
Actin binding: the LKKTETQ segment of Tβ4 is the region that binds actin and drives its effects on cell migration.[4]
Wound repair: in a rat full-thickness wound model, Tβ4 increased re-epithelialization, collagen deposition and angiogenesis, and it raised keratinocyte migration 2- to 3-fold in vitro.[6]
Cell survival: in the heart, Tβ4 formed a complex with PINCH and integrin-linked kinase and activated the survival kinase Akt.[7]
Most of the mechanistic work on Tβ4 used the full-length protein, so it may not apply directly to the short fragment.
Research Applications
Preclinical findings
Combination in rat Achilles tendon repair (2026): 32 rats were randomized to control, BPC-157, TB-500 or both for four weeks after tendon transection and repair. TB-500 significantly increased maximum load to failure and improved histological scores; BPC-157 improved scores numerically without statistical significance for total scores; the combination improved one histological score but did not confer additional benefit over either agent alone. The authors call the study exploratory.[8]
BPC-157 alone in rat Achilles tendon (2003): improved load to failure, functional index and collagen formation after transection.[1]
Tβ4 in rat skin wounds (1999): faster re-epithelialization with more collagen and new vessels.[6]
Laboratory research applications
Tendon and ligament models: biomechanics, histology and collagen I/III organization.
Wound and angiogenesis assays: migration, tube formation and VEGFR2 signaling.
Combination design: controlled studies usually include each single peptide as a comparator: BPC-157 and TB-500. The GLOW and KLOW blends add GHK-Cu (and KPV in KLOW).
BPC-157 lacks FDA approval and is banned in professional sports, and TB-500 is not approved by the EMA or the FDA.[5][9] This product is sold for laboratory research only.
Storage & Handling Guidelines
Proper storage and handling are essential to maintain peptide integrity and ensure reliable research results. All Pepitiva Biolabs peptides are supplied as lyophilized (freeze-dried) powder, which provides excellent long-term stability when stored correctly. Store lyophilized peptides at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted, peptide solutions should be stored at 2-8°C and used within the timeframe specified in the product documentation. Always use sterile bacteriostatic water for reconstitution and handle peptides in a clean laboratory environment to prevent contamination. Avoid repeated freeze-thaw cycles, as thermal stress can cause peptide degradation and loss of biological activity.
Quality Control & Certification
This product is manufactured under strict quality control protocols and has been verified through comprehensive analytical testing. Each batch undergoes reverse-phase HPLC analysis for purity determination and electrospray ionization mass spectrometry (ESI-MS) for molecular identity confirmation. A detailed Certificate of Analysis (COA) is available for download, documenting purity percentage, molecular weight verification, appearance, and recommended storage conditions. Pepitiva Biolabs maintains batch-level traceability from synthesis through delivery, ensuring complete transparency and quality assurance for your research.
Frequently Asked Questions
What is in the BPC-157 + TB-500 vial?
Equal amounts by mass of BPC-157 and TB-500, lyophilized together at ≥98% purity. The 10 mg vial contains 5 mg of each peptide.
Has the BPC-157 and TB-500 combination been studied?
Yes, in one published rat study (2026) of Achilles tendon repair. TB-500 alone gave the clearest biomechanical improvement, and the combination did not add benefit over either peptide alone. We found no human study of the combination.
What is the difference between BPC-157 and TB-500?
They are unrelated. BPC-157 is a 15-amino-acid peptide based on a gastric juice protein; TB-500 is based on thymosin beta-4, an actin-binding protein. See BPC-157 and TB-500.
Is the TB-500 in this blend full thymosin beta-4 or a fragment?
The name TB-500 is used both for the acetylated 7-residue fragment Ac-LKKTETQ and for full-length thymosin beta-4. Check the Certificate of Analysis for the identity of the TB-500 in your batch.
Are BPC-157 and TB-500 approved?
No. Neither is approved for human or veterinary use, and BPC-157 is banned in professional sports.
How should the blend be stored?
Keep the lyophilized powder at −20 °C, protected from light and moisture.
Is this product approved for human use?
No. This product is intended exclusively for in vitro scientific research and laboratory use. It is not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and should not be administered to humans or animals under any circumstances.
How do I reconstitute this peptide?
Add sterile bacteriostatic water slowly to the vial, directing the stream against the glass wall rather than directly onto the lyophilized powder. Gently swirl the vial until the powder is fully dissolved — do not shake vigorously. The recommended reconstitution volume depends on your desired concentration. Refer to the product documentation for specific guidance.
Can I get a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis is included with every order and is also available for download from the product page. The COA documents HPLC purity, mass spectrometry identity confirmation, batch number, production date, and storage recommendations.
Scientific References
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PubMed
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. PubMed
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed
Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed
Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464. PubMed
Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PubMed
Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed
PubChem. BPC-157, CID 9941957: C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0. Source
Sources are peer-reviewed publications indexed in PubMed and trial registrations on ClinicalTrials.gov. Each citation was checked against its PubMed record.
For research use only. Not for human consumption.
Related Peptides
New≥99%
Metabolic
BPC-157
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide, a chain of 15 amino acids wi...
